Chapter/Section Purchase

1 Antisense and RNA Interference Therapeutics Market Overview
1.1 Product Overview and Scope of Antisense and RNA Interference Therapeutics
1.2 Antisense and RNA Interference Therapeutics Segment by Type
1.2.1 Global Antisense and RNA Interference Therapeutics Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 RNA
1.2.3 Antisense RNA
1.3 Antisense and RNA Interference Therapeutics Segment by Application
1.3.1 Global Antisense and RNA Interference Therapeutics Sales Comparison by Application: (2022-2028)
1.3.2 General Hospitals
1.3.3 Specialty Clinics
1.4 Global Antisense and RNA Interference Therapeutics Market Size Estimates and Forecasts
1.4.1 Global Antisense and RNA Interference Therapeutics Revenue 2017-2028
1.4.2 Global Antisense and RNA Interference Therapeutics Sales 2017-2028
1.4.3 Antisense and RNA Interference Therapeutics Market Size by Region: 2017 Versus 2021 Versus 2028
2 Antisense and RNA Interference Therapeutics Market Competition by Manufacturers
2.1 Global Antisense and RNA Interference Therapeutics Sales Market Share by Manufacturers (2017-2022)
2.2 Global Antisense and RNA Interference Therapeutics Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Antisense and RNA Interference Therapeutics Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Antisense and RNA Interference Therapeutics Manufacturing Sites, Area Served, Product Type
2.5 Antisense and RNA Interference Therapeutics Market Competitive Situation and Trends
2.5.1 Antisense and RNA Interference Therapeutics Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Antisense and RNA Interference Therapeutics Players Market Share by Revenue
2.5.3 Global Antisense and RNA Interference Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Antisense and RNA Interference Therapeutics Retrospective Market Scenario by Region
3.1 Global Antisense and RNA Interference Therapeutics Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Antisense and RNA Interference Therapeutics Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Antisense and RNA Interference Therapeutics Market Facts & Figures by Country
3.3.1 North America Antisense and RNA Interference Therapeutics Sales by Country
3.3.2 North America Antisense and RNA Interference Therapeutics Revenue by Country
3.3.3 United States
3.3.4 Canada
3.4 Europe Antisense and RNA Interference Therapeutics Market Facts & Figures by Country
3.4.1 Europe Antisense and RNA Interference Therapeutics Sales by Country
3.4.2 Europe Antisense and RNA Interference Therapeutics Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Antisense and RNA Interference Therapeutics Market Facts & Figures by Region
3.5.1 Asia Pacific Antisense and RNA Interference Therapeutics Sales by Region
3.5.2 Asia Pacific Antisense and RNA Interference Therapeutics Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 China Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America Antisense and RNA Interference Therapeutics Market Facts & Figures by Country
3.6.1 Latin America Antisense and RNA Interference Therapeutics Sales by Country
3.6.2 Latin America Antisense and RNA Interference Therapeutics Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.6.6 Colombia
3.7 Middle East and Africa Antisense and RNA Interference Therapeutics Market Facts & Figures by Country
3.7.1 Middle East and Africa Antisense and RNA Interference Therapeutics Sales by Country
3.7.2 Middle East and Africa Antisense and RNA Interference Therapeutics Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Antisense and RNA Interference Therapeutics Historic Market Analysis by Type
4.1 Global Antisense and RNA Interference Therapeutics Sales Market Share by Type (2017-2022)
4.2 Global Antisense and RNA Interference Therapeutics Revenue Market Share by Type (2017-2022)
4.3 Global Antisense and RNA Interference Therapeutics Price by Type (2017-2022)
5 Global Antisense and RNA Interference Therapeutics Historic Market Analysis by Application
5.1 Global Antisense and RNA Interference Therapeutics Sales Market Share by Application (2017-2022)
5.2 Global Antisense and RNA Interference Therapeutics Revenue Market Share by Application (2017-2022)
5.3 Global Antisense and RNA Interference Therapeutics Price by Application (2017-2022)
6 Key Companies Profiled
6.1 Alnylam Pharmaceuticals
6.1.1 Alnylam Pharmaceuticals Corporation Information
6.1.2 Alnylam Pharmaceuticals Description and Business Overview
6.1.3 Alnylam Pharmaceuticals Antisense and RNA Interference Therapeutics Sales, Revenue and Gross Margin (2017-2022)
6.1.4 Alnylam Pharmaceuticals Antisense and RNA Interference Therapeutics Product Portfolio
6.1.5 Alnylam Pharmaceuticals Recent Developments/Updates
6.2 Antisense Therapeutics
6.2.1 Antisense Therapeutics Corporation Information
6.2.2 Antisense Therapeutics Description and Business Overview
6.2.3 Antisense Therapeutics Antisense and RNA Interference Therapeutics Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Antisense Therapeutics Antisense and RNA Interference Therapeutics Product Portfolio
6.2.5 Antisense Therapeutics Recent Developments/Updates
6.3 Arbutus Biopharma
6.3.1 Arbutus Biopharma Corporation Information
6.3.2 Arbutus Biopharma Description and Business Overview
6.3.3 Arbutus Biopharma Antisense and RNA Interference Therapeutics Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Arbutus Biopharma Antisense and RNA Interference Therapeutics Product Portfolio
6.3.5 Arbutus Biopharma Recent Developments/Updates
6.4 Ionis Pharmaceuticals
6.4.1 Ionis Pharmaceuticals Corporation Information
6.4.2 Ionis Pharmaceuticals Description and Business Overview
6.4.3 Ionis Pharmaceuticals Antisense and RNA Interference Therapeutics Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Ionis Pharmaceuticals Antisense and RNA Interference Therapeutics Product Portfolio
6.4.5 Ionis Pharmaceuticals Recent Developments/Updates
6.5 F. Hoffmann-La Roche
6.5.1 F. Hoffmann-La Roche Corporation Information
6.5.2 F. Hoffmann-La Roche Description and Business Overview
6.5.3 F. Hoffmann-La Roche Antisense and RNA Interference Therapeutics Sales, Revenue and Gross Margin (2017-2022)
6.5.4 F. Hoffmann-La Roche Antisense and RNA Interference Therapeutics Product Portfolio
6.5.5 F. Hoffmann-La Roche Recent Developments/Updates
6.6 Santaris
6.6.1 Santaris Corporation Information
6.6.2 Santaris Description and Business Overview
6.6.3 Santaris Antisense and RNA Interference Therapeutics Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Santaris Antisense and RNA Interference Therapeutics Product Portfolio
6.6.5 Santaris Recent Developments/Updates
6.7 Silence Therapeutics
6.6.1 Silence Therapeutics Corporation Information
6.6.2 Silence Therapeutics Description and Business Overview
6.6.3 Silence Therapeutics Antisense and RNA Interference Therapeutics Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Silence Therapeutics Antisense and RNA Interference Therapeutics Product Portfolio
6.7.5 Silence Therapeutics Recent Developments/Updates
6.8 Sirnaomics
6.8.1 Sirnaomics Corporation Information
6.8.2 Sirnaomics Description and Business Overview
6.8.3 Sirnaomics Antisense and RNA Interference Therapeutics Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Sirnaomics Antisense and RNA Interference Therapeutics Product Portfolio
6.8.5 Sirnaomics Recent Developments/Updates
6.9 Tekmira Pharmaceuticals
6.9.1 Tekmira Pharmaceuticals Corporation Information
6.9.2 Tekmira Pharmaceuticals Description and Business Overview
6.9.3 Tekmira Pharmaceuticals Antisense and RNA Interference Therapeutics Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Tekmira Pharmaceuticals Antisense and RNA Interference Therapeutics Product Portfolio
6.9.5 Tekmira Pharmaceuticals Recent Developments/Updates
7 Antisense and RNA Interference Therapeutics Manufacturing Cost Analysis
7.1 Antisense and RNA Interference Therapeutics Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Antisense and RNA Interference Therapeutics
7.4 Antisense and RNA Interference Therapeutics Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Antisense and RNA Interference Therapeutics Distributors List
8.3 Antisense and RNA Interference Therapeutics Customers
9 Antisense and RNA Interference Therapeutics Market Dynamics
9.1 Antisense and RNA Interference Therapeutics Industry Trends
9.2 Antisense and RNA Interference Therapeutics Market Drivers
9.3 Antisense and RNA Interference Therapeutics Market Challenges
9.4 Antisense and RNA Interference Therapeutics Market Restraints
10 Global Market Forecast
10.1 Antisense and RNA Interference Therapeutics Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Antisense and RNA Interference Therapeutics by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Antisense and RNA Interference Therapeutics by Type (2023-2028)
10.2 Antisense and RNA Interference Therapeutics Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Antisense and RNA Interference Therapeutics by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Antisense and RNA Interference Therapeutics by Application (2023-2028)
10.3 Antisense and RNA Interference Therapeutics Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Antisense and RNA Interference Therapeutics by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Antisense and RNA Interference Therapeutics by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer